Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel
This article was originally published in The Pink Sheet Daily
Executive Summary
Buyout of the private U.S. pharma company gives Sandoz a portfolio of generic drug candidates and technologies in asthma and COPD.
You may also be interested in...
'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
Swiss group plans to outpace industry growth through maintaining R&D investment across chosen areas, and through improving efficiency.
'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
Swiss group plans to outpace industry growth through maintaining R&D investment across chosen areas, and through improving efficiency.
Respiratory Generics: Big Potential But A Tough Market To Crack
With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity